#eBRAVE_AF trial: #AFib screening using conventional smartphones more than doubles the detection and treatment rate in older people compared to routine screening.
#ESCCongress
#PERSPECTIVE trial: sacubitril/valsartan does not change cognitive function, compared with valsartan, in patients with #heartfailure and mildly reduced or preserved ejection fraction.
#ESCCongress
Muscedere, J. The Need to Implement Frailty in the International Classification of Disease (ICD). J Frailty Aging 9, 2–3 (2020). https://t.co/XliFDj0ADe
This interactive feature about screening for atrial fibrillation in asymptomatic older adults offers a case vignette accompanied by two essays, one supporting screening and the other supporting deferral of screening. https://t.co/dfmDjaveXm
The ELDERCARE-AF trial showed that very low dose edoxaban was superior to placebo in reducing #Stroke or systemic embolism among Japanese #AFib patients ≥80 years of age. Learn more about the clinical trial here: https://t.co/RnushPXVPr #NOAC#cvCoag@DLBHATTMD
What are the patterns and predictors of #Statin use among patients with atherosclerotic #CVD? Find out more here: https://t.co/o3ZvN32UmB #cvLipids#cvPrev
Efficacy and Safety of Dapagliflozin According to Frailty in Heart Failure With Reduced Ejection Fraction: A Post Hoc Analysis of the DAPA-HF Trial: Annals of Internal Medicine: Vol 0, No 0 https://t.co/4nipTH7Hqp @IcyfaSemi@GiuseppeGalati_@Medtorek@chemachir@mendez_bailon
Effect of 15-mg Edoxaban on Clinical Outcomes in 3 Age Strata in Older Patients With Atrial Fibrillation: A Prespecified Subanalysis of the ELDERCARE–AF Randomized Clinical Trial | Atrial Fibrillation | JAMA Cardiology | JAMA Network https://t.co/ruFUI9jLTE
Association of Blood Pressure With Cognitive Decline, #Dementia, and Mortality: Efforts are required to control long-term systolic BP and pulse pressure and to maintain adequate diastolic BP
#hypertension
https://t.co/yKlnDEgkrU